-+ 0.00%
-+ 0.00%
-+ 0.00%

ACTINIUM PHARMACEUTICALS - NO DOSE-LIMITING TOXICITIES OR GRADE 3/4 ADVERSE EVENTS OBSERVED IN INITIAL COHORT

Reuters·10/20/2026 12:02:08

Please log in to view news